[go: up one dir, main page]

IL155818A0 - Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridyl-sulfonamide and cyclic oligosaccharides - Google Patents

Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridyl-sulfonamide and cyclic oligosaccharides

Info

Publication number
IL155818A0
IL155818A0 IL15581801A IL15581801A IL155818A0 IL 155818 A0 IL155818 A0 IL 155818A0 IL 15581801 A IL15581801 A IL 15581801A IL 15581801 A IL15581801 A IL 15581801A IL 155818 A0 IL155818 A0 IL 155818A0
Authority
IL
Israel
Prior art keywords
methylethylaminocarbonyl
methylphenylamino
sulfonamide
pyridyl
compositions
Prior art date
Application number
IL15581801A
Other languages
English (en)
Original Assignee
Pliva Pharm & Chem Works
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Pharm & Chem Works filed Critical Pliva Pharm & Chem Works
Publication of IL155818A0 publication Critical patent/IL155818A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL15581801A 2000-11-10 2001-01-31 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridyl-sulfonamide and cyclic oligosaccharides IL155818A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HR20000765A HRP20000765A2 (en) 2000-11-10 2000-11-10 Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
PCT/HR2001/000004 WO2002038186A1 (en) 2000-11-10 2001-01-31 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides

Publications (1)

Publication Number Publication Date
IL155818A0 true IL155818A0 (en) 2003-12-23

Family

ID=10947206

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15581801A IL155818A0 (en) 2000-11-10 2001-01-31 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridyl-sulfonamide and cyclic oligosaccharides

Country Status (26)

Country Link
US (1) US7037928B2 (es)
EP (1) EP1347780B1 (es)
JP (1) JP2004513155A (es)
KR (1) KR20030060929A (es)
CN (1) CN1477977A (es)
AR (1) AR026815A1 (es)
AU (1) AU2001228721A1 (es)
BG (1) BG107896A (es)
BR (1) BR0115281A (es)
CA (1) CA2428179A1 (es)
CZ (1) CZ20031490A3 (es)
DE (1) DE60125828T2 (es)
EA (1) EA005111B1 (es)
EE (1) EE200300197A (es)
GE (1) GEP20043403B (es)
HR (1) HRP20000765A2 (es)
HU (1) HUP0400776A2 (es)
IL (1) IL155818A0 (es)
IS (1) IS6810A (es)
MX (1) MXPA03004111A (es)
NO (1) NO20032091L (es)
PL (1) PL361667A1 (es)
SK (1) SK6722003A3 (es)
WO (1) WO2002038186A1 (es)
YU (1) YU35303A (es)
ZA (1) ZA200303601B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI21703A (en) * 2004-01-14 2005-08-31 Lek Farmacevtska Druzba Dd Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
ATE375977T1 (de) * 2004-01-22 2007-11-15 Pfizer Sulfonamidderivate zur behandlung von krankheiten
CN100372534C (zh) * 2006-04-20 2008-03-05 南京海辰药业有限公司 托拉塞米冻干制剂及制备方法
JP5469595B2 (ja) 2007-04-13 2014-04-16 ミレニアム ファーマシューティカルズ, インコーポレイテッド 第Xa因子阻害薬として作用する化合物との併用抗凝固療法
BR102012009317B1 (pt) * 2012-04-20 2022-05-31 Universidade Federal De Minas Gerais - Ufmg Processo de preparação de compostos de inclusão envolvendo ciclodextrinas e fármacos, usando um sistema de fluxo contínuo
JP6837190B2 (ja) * 2015-06-16 2021-03-03 エイティーエックスエー セラピューティクス リミテッド トロンボキサン受容体アンタゴニスト
EP3893843B1 (en) 2018-12-10 2025-07-30 SQ Innovation AG Pharmaceutical compositions of furosemide and uses thereof
US11246851B2 (en) 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576511A (en) * 1897-02-02 Georg steinike and friedrich schmidt
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
KR100485459B1 (ko) * 1995-12-01 2005-08-31 코닌클리케 필립스 일렉트로닉스 엔.브이. 디지탈무선전화시스템,무선기지국,및무선기지국과무선핸드셋을포함하는무선전화시스템
US6828334B2 (en) * 2002-05-23 2004-12-07 Usv Limited Fenofibrate-cyclodextrin inclusion complexes and their pharmaceutical composition

Also Published As

Publication number Publication date
AU2001228721A1 (en) 2002-05-21
EP1347780B1 (en) 2007-01-03
CZ20031490A3 (cs) 2003-08-13
BG107896A (bg) 2004-01-30
JP2004513155A (ja) 2004-04-30
HRP20000765A2 (en) 2002-06-30
US7037928B2 (en) 2006-05-02
PL361667A1 (en) 2004-10-04
EA200300556A1 (ru) 2003-08-28
DE60125828T2 (de) 2007-08-16
GEP20043403B (en) 2004-06-10
HUP0400776A2 (hu) 2004-08-30
YU35303A (sh) 2006-03-03
BR0115281A (pt) 2003-07-29
DE60125828D1 (de) 2007-02-15
EE200300197A (et) 2003-08-15
MXPA03004111A (es) 2004-05-05
WO2002038186A1 (en) 2002-05-16
NO20032091L (no) 2003-07-02
EP1347780A1 (en) 2003-10-01
IS6810A (is) 2003-05-08
US20040039204A1 (en) 2004-02-26
SK6722003A3 (en) 2003-10-07
EA005111B1 (ru) 2004-10-28
CN1477977A (zh) 2004-02-25
CA2428179A1 (en) 2002-05-16
NO20032091D0 (no) 2003-05-09
ZA200303601B (en) 2004-07-19
AR026815A1 (es) 2003-02-26
KR20030060929A (ko) 2003-07-16

Similar Documents

Publication Publication Date Title
HUP0300203A3 (en) Novel cyclic amide derivatives, and pharmaceutical compositions containing same
EP1251953A4 (en) MODIFIED RHEOLOGY COMPOSITIONS AND MODIFICATION AGENTS
AU8670901A (en) Fabric care compositions comprising cationic silicones and methods employing same
HUP0400048A3 (en) N-aroyl cyclic amines and pharmaceutical compositions containing them
HUP0303621A3 (en) Pharmaceutical compositions containing combinations comprising an antidiarrheal agent and epothilone or an epothilone
AU6118001A (en) Combination therapeutic compositions and methods of use
HUP0300409A3 (en) Pharmaceutical compositions containing antiadhesive carbohydrates and their use
SI1499589T1 (sl) Derivati N-(fenil(piperidin-2-il)metil)benzamida,njihova priprava in njihova terapevtska uporaba
IL141767A0 (en) Use of heteroaryl substituted n- (indole-2-carbonyl-) amides for treatment of infection
GB2368537B (en) Dynamic damper and dynamic damper-installed racket
HUP0301713A3 (en) Pharmaceutical compositions containing propenone derivatives and their use
HUP0402318A3 (en) Pharmaceutical composition comprising cyclosporin and use thereof
GB0108470D0 (en) Pharmaceutical compositions and their use
IL155818A0 (en) Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridyl-sulfonamide and cyclic oligosaccharides
AU1365102A (en) Pour-on application method and devices
AU2001257457A1 (en) Vibration dampening compositions and methods thereof
HUP0401733A3 (en) Cyclic amine-derivatives and pharmaceutical compositions containing them
SG100745A1 (en) Ceramic composition and ceramic capacitor
PL367676A1 (en) Novel heterocyclic derivatives and medicinal use thereof
IL153487A0 (en) Pharmaceutical compositions and methods for use
AU3022201A (en) Novel use of (R)-(-)-2-(5-(4-fluorophenyl)-3-pyridylmethylaminomethyl)- chromane and its physiologically aceptable salts
IL153897A0 (en) Pharmaceutical compositions and methods for use
DE60139151D1 (de) Haarwuchshemmer und diese enthaltende zusammensetzungen
HUP0303936A3 (en) Novel composition and use
ATE350065T1 (de) Zusammensetzungen aus n- (methylethylaminocarbonyl)-4-(3- methylphenylamino)-3-pyridylsulfonamid und zyklischen oligonukleotiden